2019
- Lockery JE, Collyer TA, Reid CM, Ernst ME, Gilbertson D, Hay N, Kirpach B, McNeil JJ, Nelson MR, Orchard SG, Pruksawongsin K, Shah RC, Wolfe R, Woods RL & on behalf of the ASPREE Investigator Group. Overcoming challenges to data quality in the ASPREE clinical trial. Trials 2019, 20: 686 doi:10.1186/s13063-019-3789-2
- Davis SR, Bell RJ, Robinson PJ, Handelsman DJ, Gilbert T, Phung J, Desai R, Lockery JE, Woods RL, Wolfe RS, Reid CM, Nelson MR, Murray AM, McNeil JJ. Testosterone and estrone increase from the age of 70 years; findings from the Sex Hormones in Older Women Study. J Clinical Endocrinology & Metabolism, 2019 Aug 13; pii: jc.2019-00743. doi: 10.1210/jc.2019-00743. [Epub ahead of print]
- Agustini B, Mohebbi M, Woods RL, McNeil JJ, Nelson MR, Shah RC, Murray AM, Ernst ME, Reid CM, Tonkin A, Lockery JE, Berk M. ASPREE Investigator Group. Association Between Statin Use and Depressive Symptoms in a Large Community-Dwelling Older Population Living in Australia and the USA: A Cross-Sectional Study. CNS Drugs. 2019 May 6. doi: 10.1007/s40263-019-00633-3 [Epub ahead of print]
- Polkinghorne KR, Wolfe R, Jachno KM, Wetmore JB, Woods RL, McNeil JJ, Nelson MR, Reid CM, Murray AM; ASPREE Investigator Group. Prevalence of chronic kidney disease in the elderly using the ASPirin in Reducing Events in the Elderly study cohort. Nephrology 2019 24:1248-1256. doi: 10.1111/nep.13565
- Mohebbi M, Agustini B, Woods RL, McNeil JJ, Nelson MR, Shah RC, Nguyen V, Storey E, Murray AM, Reid CM, Kirpach B, Wolfe RS, Lockery JE, Berk M; ASPREE Investigator Group. Prevalence of depressive symptoms and its associated factors among healthy community-dwelling older adults living in Australia and the United States. Int J Geriatr Psychiatry. 2019 Apr 16. doi: 10.1002/gps.5119 [Epub ahead of print]
- Lockery JE, Collyer TA, Abhayaratna WP, Fitzgerald SM, McNeil JJ, Nelson MR, Orchard SG, Reid C, Stocks NP, Trevaks RE, Woods RL. Recruiting general practice patients for large clinical trials: lessons from the Aspirin in Reducing Events in the Elderly (ASPREE) study. Med J Aust 2019; 210 (4): 168-173. doi: 10.5694/mja2.12060
- COMMENTARY Chan AT, McNeil J. Aspirin and Cancer Prevention in the Elderly: Where Do We Go From Here? Gastroenterology. 2019 Feb;156(3):534-538. doi: 10.1053/j.gastro.2018.11.063
- McNeil JJ, Woods RL, Ward SA, Britt CJ, Lockery JE, Beilin LJ, Owen AJ. Cohort Profile: The ASPREE Longitudinal Study of Older Persons (ALSOP). International Journal of Epidemiology, 2019. doi:https://doi.org/10.1093/ije/dyy279
2018
- Lacaze P, Pinese M, Kaplan W, Stone A, Brion M, Woods RL, McNamara M, McNeil JJ, Dinger ME, Thomas DM. The Medical Genome Reference Bank: a whole-genome data resource of 4,000 healthy elderly individuals. Rationale and cohort design. European Journal of Human Genetics, 2018. doi: 10.1038/s41431-018-0279-z
- Stocks N, González-Chica DA, Lockery JE, Shah RC, Murray AM, Wolfe R, Nelson MR, Reid CM, McNeil JJ, Woods RL, on behalf of the ASPREE Investigator Group. Quality of Life for 19,114 participants in the ASPREE (Aspirin in Reducing Events in the Elderly) Study and their association with sociodemographic and lifestyle modifiable risk factors. Quality of Life Research, 2018, pp.1-12. doi: 10.1007/s11136-018-2040-z
- McNeil JJ*, Woods RL*, Nelson MR, Reid CM, Kirpach B, Wolfe R, Storey E, Shah RC, Lockery JE, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Ryan J, Radziszewska B, Grimm R & Murray AM, on behalf of the ASPREE Investigator Group (* joint first authors). Effect of aspirin on disability-free survival in the healthy elderly. New England Journal of Medicine, 2018, 379:1499-1508. doi: 10.1056/nejmoa1800722
- McNeil JJ*, Nelson MR*, Woods RL, Lockery JE, Wolfe R, Reid CM, Kirpach B, Shah RC, Ives DG, Storey E, Ryan J, Tonkin AM, Newman AB, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Radziszewska B, Grimm R & Murray AM, on behalf of the ASPREE Investigator Group (* joint first authors). Effect of aspirin on all-cause mortality in the healthy elderly. New England Journal of Medicine, 2018, 379:1499-1508. doi: 10.1056/NEJMoa1803955
- McNeil JJ, Wolfe R, Woods RL, Tonkin AM, Donnan GA, Nelson MR, Reid CM, Lockery JE, Kirpach B, Storey E, Shah RC, Williamson JD, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Orchard SG, Trevaks RE, Beilin LJ, Johnston CI, Ryan J, Radziszewska B, Jelinek M, Malik M, Eaton C, Brauer D, Cloud G, Wood E, Mahady SE, Satterfield S, Grimm R & Murray AM, on behalf of the ASPREE Investigator Group. Effect of aspirin on cardiovascular events and bleeding in the healthy elderly. New England Journal of Medicine, 2018, 379:1499-1508. doi: 10.1056/nejmoa1805819
- Ryan J, Woods RL, Britt C, Murray AM, Shah RC, Reid CM, Kirpach B, Wolfe RS, Nelson MR, Lockery JE, Orchard SG, Trevaks RE, McNeil JJ, Storey E; on behalf of the ASPREE Investigator Group. Normative performance of healthy older individuals on the Modified Mini-Mental State (3MS) examination according to ethno-racial group, gender, age, and education level. The Clinical Neuropsychologist, published online Jul 2018. doi.org/10.1080/13854046.2018.1488996
- Margolis KL, Mahady SE, Nelson MR, Ives DG, Satterfield S, Britt C, Ekram S, Lockery JE, Schwartz EC, Woods RL, McNeil JJ, Wood EM. Development of a standardized definition for clinically significant bleeding in the ASPirin in Reducing Events in the Elderly (ASPREE) trial. Contemporary Clinical Trials Communications, 2018, Vol 11, 30-36. doi.org/10.1016/j.conctc.2018.05.015
- Wolfe R, Murray AM, Woods, RL, Kirpach B, Gilbertson D, Shah RC, Nelson MR, Reid CM, Ernst ME, Lockery JE, Donnan GA, Williamson J, McNeil JJ. The aspirin in reducing events in the elderly trial: Statistical analysis plan. International Journal of Stroke, 2018, Vol.13(3), pp.335-338. doi.org/10.1177/1747493017741383
- Fransquet PD, Lacaze P, Woods RL, McNeil JJ, Saffery R, Ryan J. Blood DNA methylation as a potential biomarker of dementia: a systematic review. Alzheimer’s & Dementia, 2017, 14(1): 81-103. IF:11.0. DOI: 10.1016/j.jalz.2017.10.002.
- Jamadar SD, Sforazzini F, Raniga P, Ferris NJ, Paton B, Bailey MJ, Brodtmann A, Yates PA, Donnan GA, Ward SA, Woods RL, Storey E, McNeil JJ, Egan GF, ASPREE Investigator Group. Sexual Dimorphism of Resting-State Network Connectivity in Healthy Ageing. The Journals of Gerontology: Series B, , gby004, doi.org/10.1093/geronb/gby004
- Ward SA, Storey E, Woods RL, Hamilton GS, Kawasaki R, Janke AL, Naughton MT, O’Donoghue F, Wolfe R, Wong TY, Reid CM, Abhayaratna WP, Stocks N, Trevaks R, Fitzgerald S, Hodgson LAB, Robman L, Workman B, Mcneil JJ. The Study of Neurocognitive Outcomes, Radiological and Retinal Effects of Aspirin in Sleep Apnoea- rationale and methodology of the SNORE-ASA study. Contemporary clinical trials, 2018, Vol.64, pp.101-111. doi.org/10.1016/j.cct.2017.10.016
- Mohebbi M, Nguyen V, McNeil JJ, Woods RL, Nelson MR, Shah RC, Storey E, Murray AM, Reid CM, Kirpach B, Wolfe, R, Lockery JE, Berk M, ; on behalf of the ASPREE investigator group. Psychometric properties of a short form of the Center for Epidemiologic Studies Depression (CES-D-10) scale for screening depressive symptoms in healthy community dwelling older adults. General Hospital Psychiatry, 2018; 51:118-125. doi: 10.1016/j.genhosppsych.2017.08.002.
2017
- McNeil JJ, Woods RL, Nelson MR, Murray AM, Reid CM, Kirpach B, Storey E, Shah RC, Wolfe R, Tonkin AM, Newman AB, Williamson JD, Lockery JE, Margolis KL, Ernst ME, Abhayaratna WP, Stocks N, Fitzgerald SM, Trevaks RE, Orchard SG, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Grimm RH; on behalf of the ASPREE investigator group. Baseline Characteristics of Participants in the ASPREE (ASPirin in Reducing Events in the Elderly) Study. J Gerontol A Biol Sci Med Sci, 2017, Vol. 00, No. 00, 1–8. doi:10.1093/gerona/glw342
- Ward SA, Raniga P, Ferris NJ, Woods RL, Storey E, Bailey MJ, Brodtmann A, Yates PA, Donnan GA, Trevaks RE, Wolfe R, Egan GF, McNeil JJ; (Joint Senior authorship); on behalf of the ASPREE investigator group. ASPREE-NEURO study protocol: A randomized controlled trial to determine the effect of low-dose aspirin on cerebral microbleeds, white matter hyperintensities, cognition, and stroke in the healthy elderly. Int J Stroke. 2017;12(1):108-113. doi:10.1177/1747493016669848
- Lacaze P, Winship I, McNeil JJ. Penetrance and the Healthy Elderly. Genetic testing and molecular biomarkers, 2017, Vol.21(11), pp.637-640 doi.org/10.1089/gtmb.2017.0126
- Robman L, Guymer R, Woods RL, Ward SA, Wolfe R, Phung J, Hodgson L, Makeyeva G, Aung KZ, Gilbert T, Lockery JE, Le-Pham Y, Orchard S, Storey E, Abhayaratna W, Reid D, Ernst ME, Nelson MR, Reid C, McNeil, JJ. Age-related macular degeneration in a randomized controlled trial of low-dose aspirin: Rationale and study design of the ASPREE-AMD study. Contemporary Clinical Trials Communications, 2017, Vol.6, pp.105-114. doi:10.1016/j.conctc.2017.03.005
- Lacaze P, Ryan J, Woods RL, Winship I, McNeil JJ. Pathogenic variants in the healthy elderly: unique ethical and practical challenges. Journal of Medical Ethics, 2017, Vol. 43(10), p.714 DOI: 10.1136/medethics-2016-103967
- Lacaze P, Woods RL, Zoungas S, McNeil JJ. The genomic potential of the Aspirin in Reducing Events in the Elderly and Statins in Reducing Events in the Elderly studies. Internal medicine Journal, 2017, Vol.47(4), pp.461-463 doi.org/10.1111/imj.13384
- Eisen DP, Moore EM, Leder K, Lockery JE, McBryde ES, McNeil JJ, Pilcher D, Wolfe R, Woods RL. AspiriN To Inhibit SEPSIS (ANTISEPSIS) randomised controlled trial protocol. BMJ Open. 2017;7:e013636. doi: 10.1136/bmjopen-2016-013636
2016
- Berk M, Woods RL, Nelson MR, Shah RC, Reid CM, Storey E, Fitzgerald SM, Lockery JE, Wolfe R, Mohebbi M, Murray AM, Kirpach B, Grimm R, McNeil JJ. ASPREE-D: Aspirin for the prevention of depression in the elderly. International Psychogeriatrics, 2016, doi:10.1017/S104161021600079X
2015
- Lowthian JA, Britt CJ, Rance G, Lin FR, Woods RL, Wolfe R, Nelson MR, Dillon HA, Ward S, Reid CM, Lockery JE, Nguyen TT, McNeil JJ, Storey E. Slowing the progression of age-related hearing loss: Rationale and study design of the ASPIRIN in HEARING, retinal vessels imaging and neurocognition in older generations (ASPREE-HEARING) trial. Contemp Clin Trials. 2015; 46; 60-66 doi: 10.1016/j.cct.2015.11.014
- Barker AL, McNeil JJ, Seeman E, Ward SA, Sanders KM, Khosla S, Cumming RG, Pasco JA, Bohensky MA, Ebeling PR, Woods RL, Lockery JE, Wolfe R, Talevski J, and the ASPREE Investigator Group. A randomised controlled trial of low-dose aspirin for the prevention of fractures in healthy older people: protocol for the ASPREE-Fracture substudy. Inj Prev. 2015, pii: injuryprev-2015-041655. doi: 10.1136/injuryprev-2015-041655. [Epub ahead of print] PMID: 26002770
2014
- Chong EW, Guymer RH, Robman LD. Does aspirin increase the risk of age-related macular degeneration? Expert Opinion on Drug Safety, 2014,13:691-3 doi: 10.1517/14740338.2014.914169
2013
- ASPREE Investigator Group. Study design of ASPirin in Reducing Events in the Elderly (ASPREE): a randomized, controlled trial. Contemporary Clinical Trials, 2013, 36: 555–564 doi: org/10.1016%2Fj.cct.2013.09.014
- COMMENTARY Nelson MR. General practice-based clinical trials. Perspectives, Med J Aust 2013; 198 (3): doi: 10.5694/mja12.11061
2012
- Reid CM, Storey E, Wong TY, Woods RL, Tonkin A, Wang JJ, Kam A, Janke A, Essex R, Abhayaratna WP, Budge MM; on behalf of the ASPREE Study Group. Aspirin for the prevention of cognitive decline in the elderly: rationale and design of a neuro-vascular imaging study (ENVIS-ion). BMC Neurol, 2012, 12:3. doi: 10.1186/1471-2377-12-3.
- Linden MD, Tran HA, Woods RL, Tonkin AM. High platelet reactivity and antiplatelet therapy resistance. Seminars in Thrombosis and Hemostasis, 2012, 38(2):200-12. DOI: 10.1055/s-0032-1301417
2009
- Woods RL, Tonkin AM, Nelson MR, Britt HC, Reid CM. Should aspirin be used for the primary prevention of cardiovascular disease in people with diabetes? Med J Aust, 2009, 190:614-5 PMID:19485837
2008
- Nelson MR, Reid CM, Ames DA, Beilin LJ, Donnan GA, Gibbs P, Johnston CI, Krum H, Storey E, Tonkin A, Wolfe R, Woods R, McNeil JJ. Feasibility of conducting a primary prevention trial of low-dose aspirin for major adverse cardiovascular events in older people in Australia: results from the ASPirin in Reducing Events in the Elderly (ASPREE) pilot study. Med J Aust, 2008, 189:105-109 PMID:18637782
2005
- Nelson MR, Liew D, Bertram M, Vos T. Epidemiological modelling of routine use of low-dose aspirin in Australia for the primary prevention of coronary heart disease and stroke in those aged 70 years and above. BMJ 2005; 330:1306-1308.
2003
- Nelson MR, Reid CM, Johnstone CI, Krum H, Storey E, Tonkin A, Beilin LJ, Donnan GA, McNeil JJ. After ANBP2 – ASPREE Clinical And Experimental Pharmacology And Physiology, 2003, Vol.30(7), pp.A59-A59.
- ASPREE Study Group. Nelson MR, Reid CM, Beilin LJ, Donnan GA, Johnston CI, Krum H, Storey E, Tonkin AM, McNeil JJ. Rationale for a primary prevention trial in the elderly of low dose aspirin for the prevention of major adverse cardiovascular events and vascular dementia in Australian general practice. ASPirin in Reducing Events in the Elderly (ASPREE). J Drugs and Aging. 2003; 20(12):897-903.